シナプスベシクルタンパク質SV2は,新しいタイプのトランスメブラントランスポーターです
M B Feany1, S Lee, R H Edwards
1Department of Neurobiology Harvard Medical School Boston, Massachusetts 02115.
Cell
|September 4, 1992
まとめ
シナプス胞タンパク質2 (SV2) は,新しいトランスポーターとして機能する可能性があります. その配列は,SV2が神経伝達物質をシナプス胞に輸入することを示唆しており,これは神経細胞のコミュニケーションに不可欠なプロセスです.
科学分野:
- 神経科学は神経科学である.
- 分子生物学は分子生物学である.
- 細胞生物学 細胞生物学
背景:
- シナプスは,神経伝達物質の貯蔵と放出に不可欠です.
- 神経伝達物質がシナプスベシクルに補充されるのは,陽子グラデーションに依存しているが,未知の分子機構が関与している.
- 神経伝達物質のトランスポーターを理解することは,シナプス機能を理解する鍵です.
研究 の 目的:
- 神経伝達物質のシナプスベシクルへの輸入に起因する分子機構を特定する.
- シナプスベシクルタンパク質2 (SV2) と,神経伝達物質の輸送におけるその潜在的な役割の特徴.
主な方法:
- シナプスベシクルタンパク質SV2の配列解析.
- SV2ドメインと既知のトランスポーターファミリーのバイオ情報学的比較.
主要な成果:
- SV2のアミノ酸配列は,6つのトランスメブランドメインの2つの異なるセットを明らかにします.
- N端末ドメインは,グルコーストランスポーターとの同質性を示しています.
- C端末ドメインは,プラズマ膜神経伝達物質のトランスポーターと同質性を示しています.
結論:
- SV2は,新しいタイプのトランスメブラントランスポーターとして特定されています.
- 構造的ホモロジーは,SV2が神経伝達物質のシナプスベジクルへの輸送を媒介することを示唆しています.
- この発見は,シナプス水泡のリサイクルにおける重要なステップのための分子候補を提供する.
関連する概念動画
Overview of Secretory Vesicles
8.8K
Secretory vesicles, also known as dense core vesicles (DCVs), are membrane-bound vesicles that transport secretory proteins, such as hormones or neurotransmitters. Regulated secretory vesicles transport proteins from the trans-Golgi network to the exterior of the cell. Proteins present in regulated secretory vesicles are required to be rapidly exocytosed in large amounts upon a specific stimulus.
Various proteins regulate the aggregation of molecules inside the secretory vesicles. Chromogranins...
Various proteins regulate the aggregation of molecules inside the secretory vesicles. Chromogranins...
8.8K
Fusion of Secretory Vesicles with the Plasma Membrane
15.9K
Proteins and neurotransmitters in secretory vesicles can be released from a cell upon vesicle docking, priming, and fusion with the plasma membrane. Vesicles are docked and primed in preparation for the quick exocytosis of their contents in response to a stimulus. The fusion process is mainly carried out by a SNAP Receptor or SNARE complex, consisting of synaptobrevin, syntaxin-1, and SNAP-25.
In 1993, Jim Rothman proposed that the antiparallel pairing of vesicular and transmembrane SNAREs, or...
In 1993, Jim Rothman proposed that the antiparallel pairing of vesicular and transmembrane SNAREs, or...
15.9K
SNAREs and Membrane Fusion
10.4K
Once a transport vesicle has recognized its target organelle, the vesicular membrane needs to fuse with the target membrane to unload the cargo. Transmembrane proteins called SNAREs present on organelle membranes and their vesicles, mediate vesicle fusion.
SNAREs exist in pairs that symmetrically interact and catalyze the fusion of the lipid bilayers in vesicle and target organelle. v-SNARE in the vesicle membrane are single polypeptide chains that bind to a complementary t-SNARE, composed of 2...
SNAREs exist in pairs that symmetrically interact and catalyze the fusion of the lipid bilayers in vesicle and target organelle. v-SNARE in the vesicle membrane are single polypeptide chains that bind to a complementary t-SNARE, composed of 2...
10.4K
Vesicular Tubular Clusters
2.4K
After budding out from the ER membrane, some COPII vesicles lose their coat and fuse with one another to form larger vesicles and interconnected tubules called vesicular tubular clusters or VTCs. These clusters constitute a compartment at the ER-Golgi interface known as ERGIC (Endoplasmic Reticulum Golgi Intermediate Compartment). The ERGIC is a mobile membrane-bound cargo transport system that sorts proteins secreted from ER and delivers them to the Golgi.
With the help of motor proteins such...
With the help of motor proteins such...
2.4K
Clathrin Coated Vesicles
8.1K
Clathrin-coated vesicles use endocytosis to transport receptors and lysosomal hydrolases from the Golgi to the lysosome in the late secretory pathway. Clathrin-mediated endocytosis was the first described endocytic process, and Clathrin-coated vesicles remain one of the most well-studied transport vesicles. The molecular machinery that generates clathrin-coated vesicles comprises over 50 proteins that precisely coordinate vesicle formation. Cell surface receptors concentrated in indented sites...
8.1K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
1.2K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K


